国际肺癌研究协会胸膜间皮瘤分期项目:即将出版的第9版胸膜间皮瘤TNM分类中TNM分期组修订建议
国际肺癌研究协会基于多国数据库3598例胸膜间皮瘤病例,其中2192例可分析临床分期、445例可分析病理分期,采用递归分割与合并算法及Cox模型提出第9版TNM分期组:临床分期纳入cT大小标准,病理分期与临床分期对齐。
要点
- 第9版临床分期组:I期T1N0;II期T1N1或T2N0;IIIA期T1N2、T2N1/2或任何T3;IIIB期任何T4;IV期任何M1。
- 分析集为3598例提交病例中可分析总体临床分期2192例、可分析总体病理分期445例。
- 病理分期组与临床分期组对齐后,区分度优于保留第8版病理分期组。
核心结论
- 据作者所知,这是首次将基于测量的cT分类拟议变化纳入胸膜间皮瘤临床TNM分类的修订。
- 病理TNM与临床TNM对齐。
研究设计与样本
- 国际肺癌研究协会通过电子数据采集或机构数据库批量传输收集多国数据。
- 生存期从诊断日期起计算。
- 候选分期组采用递归分割与合并算法,先对所有cM0病例用于临床分期,随后用于病理分期。
- 建立Cox模型估计各分期组的生存。
- 提交病例3598例,可分析总体临床分期2192例,可分析总体病理分期445例。
主要发现
- 递归分割与合并算法在限于cM0的总体生存结局上生成生存树,得出新拟议(第9版)cT和cN组分衍生的最佳分期组:I期(T1N0)、II期(T1N1;T2N0)、IIIA期(T1N2;T2N1/2;任何T3)、IIIB期(任何T4)、IV期(任何M1)。
- 第9版中cT与病理T描述词不同,但病理分期组与临床分期组对齐后的区分度优于保留第8版病理分期组。
关键数值与推荐
- 临床分期组:I期T1N0;II期T1N1或T2N0;IIIA期T1N2、T2N1/2或任何T3;IIIB期任何T4;IV期任何M1。
- 病理分期组与临床分期组对齐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The eighth edition of the TNM classification of pleural mesothelioma (PM) saw substantial changes in T and N components and stage groupings. The International Association for the Study of Lung Cancer collected data into a multinational database to further refine this classification. This ninth edition proposal incorporates changes proposed in the clinical (c)T component but not the pathologic T component, to include size criteria, and further refines TNM stage groupings for PM. METHODS: Data were submitted through electronic data capture or batch transfer from institutional databases. Survival was measured from diagnosis date. Candidate stage groups were developed using a recursive partitioning and amalgamation algorithm applied to all cM0 cases for clinical stage and subsequently for pathologic stage. Cox models were developed to estimate survival for each stage group. RESULTS: Of 3598 submitted cases, 2192 were analyzable for overall clinical stage and 445 for overall pathologic stage. Recursive partitioning and amalgamation generated survival tree on overall survival outcomes restricted to cM0, with newly proposed (ninth edition) cT and cN component-derived optimal stage groupings of stage I (T1N0), II (T1N1; T2N0), IIIA (T1N2; T2N1/2; any T3), IIIB (any T4), and IV (any M1). Although cT and pathologic T descriptors are different in the ninth edition, aligning pathologic stage groupings with clinical stage produced better discrimination than did retaining eighth edition pathologic stage groupings. CONCLUSIONS: To our knowledge, this revision of the clinical TNM classification for PM is the first to incorporate the measurement-based proposed changes in cT category. The pathologic TNM aligns with clinical TNM.
引用
- Nowak AK, Giroux DJ, Eisele M, et al. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Proposal for Revision of the TNM Stage Groupings in the Forthcoming (Ninth) Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2024. PMID: 38734072. doi:10.1016/j.jtho.2024.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。